News
- Author:
- Amy Karon
Publish date: April 30, 2018
Adjusted hazard ratios for overall survival were 1.75 for high versus undetectable ctDNA and 1.24 for high versus low cHGF.
News
- Author:
- Amy Karon
Publish date: April 27, 2018
Median investigator-assessed, progression-free survival was 9.6 months with alectinib and 1.4 months with chemotherapy.
News
- Author:
- Amy Karon
Publish date: April 26, 2018
The schedule missed its primary safety endpoint but led to fewer treatment discontinuations, dose reductions, and grade 3 toxicities than was previ...
News
- Author:
- Amy Karon
Publish date: April 25, 2018
Patients could sweat normally through up to 22 months of follow-up.
News
- Author:
- Amy Karon
Publish date: April 23, 2018
Among patients with inflammatory bowel disease, anti-TNF therapy led to a 78% lower rate of Parkinson’s disease.
News
- Author:
- Amy Karon
Publish date: April 20, 2018
After a median follow-up of more than 3 years, hazard ratios for overall survival were 0.44 and 0.50, favoring adjuvant chemotherapy.
News
- Author:
- Amy Karon
Publish date: April 18, 2018
Four-year event-free survival was 79.5% among complete responders and 89% among incomplete responders.
News
- Author:
- Amy Karon
Publish date: April 17, 2018
The older age of patients with rheumatoid arthritis explained most of their elevated risk of major adverse cardiovascular events.
News
- Author:
- Amy Karon
Publish date: April 16, 2018
CHICAGO – One-year rates of recurrence-free survival for adjuvant pembrolizumab and placebo were 75% and 61%, respectively, in a phase 3 trial of 1...
News
- Author:
- Amy Karon
Publish date: April 16, 2018
The majority of 20 patients with resectable NSCLC were alive and recurrence-free 1 year after surgery and nivolumab treatment.
News
- Author:
- Amy Karon
Publish date: April 15, 2018
Five-year colon cancer survival probability was 85% for highly ACS guideline–adherent patients and 76% for patients with low adherence.
News
- Author:
- Amy Karon
Publish date: April 13, 2018
Only 16% of respondents were aware of drug shortages, but more than 80% would want to be told about resultant substitutions with major or minor dif...
News
- Author:
- Amy Karon
Publish date: April 11, 2018
Multiplatform analyses identified four genetic subtypes of DLBCL that show distinct mutations, gene expression signatures, and treatment responses....
News
- Author:
- Amy Karon
Publish date: April 11, 2018
At 11-year follow-up, caffeine significantly improved visuomotor, visuoperceptual, and visuospatial performance.
News
- Author:
- Amy Karon
Publish date: April 9, 2018
The overall rate of major adverse cardiovascular events was less than 0.5% in a study of smokers who received one of three cessation therapies or p...
